News & analysis, rated.
Breaking AI developments, in-depth guides, real-world case studies, and analysis — each one rated so you know what matters.
OpenAI, Anthropic both filing for IPO as AI funding race intensifies
OpenAI and Anthropic are pursuing public offerings, marking a pivot from private funding. What the two largest frontier AI labs going public means for the industry's funding model.
Databricks seeks $165B valuation in new funding round
Databricks is in talks to raise capital at a valuation exceeding $165 billion, per The Information. The data and AI platform would rank among the highest-valued private companies globally if the round closes.
Clio Names Uber Executive President as Revenue Hits $500M
Legal software company Clio promoted Ronnie Gurion to president and COO after scaling revenue from $100M to $500M in four years. He previously led Uber for Business across 30 countries.
DeepIP buys PatentMaker to lead European patent AI market
DeepIP, which raised $40M in nine months, acquires German patent workflow tool PatentMaker. The combined platform covers the full patent lifecycle for European IP teams.
Jeff Hughes Named CEO of 8am, LawPay Parent Company
Jeff Hughes, a 30-year software executive, takes over as CEO of 8am after leading Enverus through 6x revenue growth. Here's what changes for law practice management users.
Legal firms assess AI in-house: Erste Bank leads strategy work
Andrea Miskolczi of InterAlia Consulting discusses AI readiness audits with enterprise legal teams at Lexpo Amsterdam. Learn what in-house assessments reveal about adoption readiness.
Your lawyers are uploading client data to ChatGPT right now
70% of law firms lack AI policies, leaving sensitive data exposed via unsanctioned tools. Browser-level controls can prevent it — here's what to audit first.
Clarivate Names Simon Webster as IP Segment President
Simon Webster takes the helm of Clarivate's intellectual property division. The appointment signals focus on patent analytics and trademark management in competitive markets.
Define your biologics formulation upfront to cut late-stage redesigns
Quality by Design (QbD) frameworks let biologic developers lock in stability and manufacturability early. Here's how to align formulation strategy with clinical needs before scale-up.
Cell Therapy Programs Need Assay Plans Before Clinical Trials
Deferring analytical development early is a common cause of FDA Complete Response Letters. Here's why process characterization must start in the lab, not scale-up.
Your CDMO choice shapes program risk—here's how to spot which reduces it
One-site operations with embedded project teams cut handoffs and communication gaps that quietly compound delays. How to assess your partner's risk design before signing.
Cell Therapy CDMO Market to Hit $143.6B by 2034 — What Sponsors Now Demand
The cell and gene therapy market is growing at 31% annually through 2034, pushing sponsors to outsource manufacturing early. Here's what CDMOs must prove to win deals.